Pioneering Medical Innovations
Dr. Ripal Gandhi completed the first commercial procedure with the Embrace Hydrogel Embolic System, marking the start of Instylla’s commercial launch following FDA approval.
The FDA granted premarket approval for the Embrace Hydrogel Embolic System for embolization of hypervascular tumors in peripheral arteries of 5 mm or less — the first liquid embolic approved for this indication supported by a prospective, randomized, controlled trial.
Instylla announced the appointment of Sean Boyle, who now serves as the company’s Chief Executive Officer.
Instylla announced the appointment of Daniel Davis to its Board of Directors.
Instylla submitted the final module of its premarket approval application for the Embrace Hydrogel Embolic System, including clinical study results supporting the hypervascular tumor embolization indication.
Instylla announced FDA 510(k) clearance of the Tembo Embolic System, expanding its portfolio of solutions for peripheral vascular embolization.
Clinical investigators achieve significant milestone by enrolling 150 patients with hypervascular tumors in pivotal randomized study. BEDFORD, Mass., – May
Secured financing advances Instylla’s clinical trials and commercialization readiness BEDFORD, Mass., – August 15, 2023 – Instylla, Inc., a privately
Financing to see Instylla through US Pivotal and other clinical trials BEDFORD, Mass., Oct. 14, 2020 /PRNewswire/ — Instylla, Inc., a privately held